On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a decline, ending the day at $60.6 which represents a decrease of $-2.37 or -3.76% from the prior close of $62.97. The stock opened at $62.46 and ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Verona Pharma (VRNA – Research Report). The ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot causes excessive bone mineral ...

Right now, Viking does not have any treatments that are formally approved by the FDA. Nevertheless, the company's lead ...

The company’s shares closed yesterday at $29.89. Olson covers the Healthcare sector, focusing on stocks such as Jasper Therapeutics, Viking Therapeutics, and Bicycle Therapeutics. According to ...

More than 200 employees of 23andMe are being laid off as part of the company’s ongoing cost-cutting measures. The layoffs ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

ULTY offers a 101% distribution yield but has only delivered 2.4% total performance since inception. Read why ULTY ETF's ...

In recent trading, Viking Therapeutics Inc (VKTX) stock price has shown some volatility, fluctuating -6.04% over the last five trades and 9.66% over the past 30 trades. This represents a notable shift ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

Viking Therapeutics (NASDAQ: VKTX) soared to center stage earlier this year as a potentially promising player in one of today ...